Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer

Breast

Volumn 6, Issue 4, 1997, Pages 186-189

  Robertson, J F R ^a   Howell, A ^b   De Friend, D J ^b   Blamey, R W ^a   Walton, P ^c  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; FULVESTRANT; MEGESTROL ACETATE; TAMOXIFEN;

AGE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CLINICAL ARTICLE; DRUG RESISTANCE; DRUG RESPONSE; FEMALE; HUMAN; METASTASIS; PRIORITY JOURNAL;

EID: 0030730273     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(97)90571-3     Document Type: Article

References (18)

1. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific anti-oestrogen (ICI 182,780) in tamoxifen resistant breast cancer. Lancet 1995; 345: 29-30.
2. Howell A, DeFriend D, Robertson J F R et al. Pharmacokinetics, pharmacological and antitumour effects of the specific antioestrogen ICI 182,780 in women with advanced breast cancer. Br J Cancer 1996; 74: 300-308.
3. Robertson J F R, Williams M R, Todd J, Nicholson R I, Morgan D A L, Blamey R W. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989; 25: 469-475.
4. Smith I E, Harris A L, Morgan M et al. Tamoxifen versus aminoglutethamide in advanced breast cancer: a randomised crossover trial. Br J Med 1981; 283: 1432-1434.
5. Kaye S B, Woods R L, Fox R M, Coates A S, Tattersall M H N. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. Cancer Res 1982; 42: 3445s-3447s.
6. Buzdar A V, Powell K C, Blumenschein G R. Aminoglutethimide after tamoxifen in advanced breast cancer: MD Anderson Hospital experience. Cancer Res 1982; 42: 3448s-3450s.
7. Harvey H A, Lipton A, White D S et al. Cross-over comparison of tamoxifen and amioglutethimide in advanced breast cancer. Cancer Res 1982; 42: 3451s-3453s.
8. Hayward J, Carbone P P, Heuson J C, Kumaoka S, Segaloff A, Rubens R D. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 39: 1289-1293.
9. Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J, Sellwood R A. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988; 24 1567-1572.
10. Wakeling A E, Bowler J. Steroidal pure anti-oestrogents. J Endocrinology 1987; 112: R7-R10.
11. Wakeling A E, Bowler J. Novel anti-oestrogens without partial agonist activity. J Steroid Biochem 1988; 31: 645-653.
12. Osborne C K, Coronado-Heinsohn E B, Hilsenbeck S G et al. Pure anti-oestrogens are superior to tamoxifen in a preclinical model of human breast cancer. J Natl Cancer Inst 1995; 87: 746.
13. Nicholson R I, Francis A B, McClelland R A, Manning D L, Gee J M W. Pure anti-oestrogens (ICI 164384 and ICI 182780) and breast cancer: is the attainment of complete oestrogen withdrawal worthwhile? Endocrine-Related Cancer 1994; 1: 5-17.
14. DeFriend D J, Howell A, Nicholson R I et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994; 54: 408-414.
15. Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer. Eur J Cancer 1996; 32A: 576-588.
16. Morgan L R. Megestrol acetate vs tamoxifen in advanced breast cancer in postmenopausal patients. Sem Oncol 1985; XII: 43-47.
17. Ingle J N, Creagan E T, Ahmann D L et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982; 5: 155-160.
18. Muss H B, Wells H B, Paschold E H et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5 year analysis - a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988; 6: 1098-1106.